Abstract: A neural event process, including receiving a neural response signal, decomposing the signal using at least one wavelet, differentiating phase data of the wavelets and the response signal to determine maxima and minima of the phase data and the signal, and processing the maxima and minima to determine peaks representing neural events.

Abstract: The present invention relates to nuclear methods and embryos developed therefrom. In particular, the present invention relates to a method of nuclear comprising the step of transferring a somatic cell nuclei into a zona pellucida-free, enucleated oocyte.

Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having an allergy to the Ara h 2 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 2 or derivative or homologue thereof.

Abstract: The present invention relates generally to a method of diagnosing, predicting or monitoring the development or progress of a cancer and, in particular, to a method of diagnosing, predicting or monitoring the development of or progress of prostate cancer in a mammal. The present invention more specifically provides a method for delineating early stage and advanced stage cancers, or predispositions thereto, by screening for changes in the level of two or more of inhibin-?, activin-?A, activin-?B, activin-?C, activin-?D, activin-?E or follistatin expression in a mammal. The present invention further provides a method for diagnosing or monitoring conditions associated with or characterized by the onset of a cancer.

Abstract: The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response.

Abstract: The present disclosure concerns compounds of formula (I) and pharmaceutically acceptable salts, hydrates, solvates, pharmaceutically acceptable derivatives, pro-drugs, tautomers and/or isomers thereof.

Abstract: A peptide of the formula (Xaa)n1-Xaa1-His-Thr-Asp-(Xaa)n2, wherein Xaa is any amino acid; Xaa1 is a hydrophobic amino acid, preferably Gly or Val; n1 is 0–10; and n2 is 0–10; and use thereof in regulating in vivo blood glucose levels in a human or other mammal, particularly in the treatment of Type 2 diabetes in a human. Preferably, the peptide is a tetrapeptide selected from Gly-His-Thr-Asp and Val-His-Thr-Asp. These hypoglycaemic peptides are isolated from human urine and they also have been chemically synthesized.

Abstract: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC).

Abstract: Pyrrolidinium based room temperature ionic liquids, and phosphorous and arsenic analogues, are used as electrolytes in energy storage devices including secondary lithium batteries, supercapacitors and asymmetric battery-supercapacitors. The electrolytes preferably contain lithium ions as the charge-carrying species. The electrolytes are in a liquid state at the operating temperature.

Abstract: A method of assessing cognitive impairment of a user includes presenting a visual test stimulus to the user for a pre-determined test stimulus exposure duration. The test stimulus is then masked and a response from the user is measured. The response provides information about the user's perception of a characteristic of the test stimulus together with the time taken for the user to respond. These steps are repeated to develop a user profile and cognitive impairment in the user is assessed by comparing the user profile with a reference profile. A method of assessing cognitive impairment of a user includes presenting a visual test stimulus to the user for a pre-determined test stimulus exposure duration. The test stimulus is then masked and a response from the user is measured. The response provides information about the user's perception of a characteristic of the test stimulus together with the time taken for the user to respond.

Abstract: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC).

Abstract: The present invention relates generally to a method of diagnosing, predicting or monitoring the development or progress of a condition characterised by modulation in the level of activin expression and, more particularly, a method of diagnosing, predicting or monitoring the development or progress of a condition characterised by modulation in the level of expression of activin bc subunit. The present invention still further provides methods for the therapeutic or prophylactic treatment of conditions characterised by aberrant, unwanted or otherwise inappropriate activin expression, for example, conditions characterised by over-expression or underexpression of activin and most particularly, conditions characterised by overexpression or underexpression of activin bc subunit. A further aspect of the present invention extends to agents for use in the methods of the present invention.

Abstract: The present invention relates generally to a method of modulating T cell functional activity by utilising ?-amino acid substituted peptides and to agents useful for the same. More particularly, the present invention relates to a method of modulating class I restricted T cell activity by utilising ?-amino acid substituted peptides and to agents useful for the same. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by suboptimal T cell stimulation such as that which occurs in some viral infections and in anti-tumour immunity, as well as aberrant, unwanted or otherwise inappropriate T cell functioning such as, but not limited to, graft rejection or autoimmune conditions, the present invention is further directed to methods of identifying, designing and/or modifying agents capable of modulating T cell functional activity.

Abstract: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC).

Abstract: An x-ray beam (4) from a rotating anode source (8) is passed through an object (1) via a monochromator (9) and slit member (10) in order to determine the object's internal structure. The emerging radiation that is within the acceptance angle of a crystal analyser (5) is diffracted onto a PIN diode detector (6), which records an intensity profile of the radiation detected as a function of angular position of the crystal analyser (5). The resulting profile is analysed to provide a complex refractive index profile for the object (1) across the width of the beam (4). The analysis method and apparatus utilises both absorption and refraction information, and can provide both qualitative and quantitative information on the object's structure, with the dimensions of the slit member (10) providing an analytical intensity profile.

Abstract: The present application is directed to a method of synthesis of a bicyclic or polycyclic compound of formula I or formula II: in which E, G, Y, n, m, R, R1, R2, R3, R6, R7, R8 and R9 are as defined.

Abstract: The invention provides a method for preventing or reducing the effects of oxidative stress on a substrate. The method includes the step of treating the substrate with a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is one or more substituents selected from —H, -alkyl, -alkoxy, -aryl, -aryloxy, -halogen, -amino (mono-, di- and tri-substituted), -alkylthio, —NO2, —COOH, —COOAlkyl, —CO-alkyl, —CN; R2 is one or more substituents selected from —H, -alkyl, —(CH2CH2O)n-R5, a sugar moiety; R3 is —H, -alkyl, -aryl, -alkylOR6, -alkylC(O)R6; R5 is selected from —H, -alkyl, -aryl; and R4 and R6 are independently selected from —OH, —O-alkyl, —O-polyalkyleneoxy, —O-aryl, —OC(O)O-alkyl, —S-alkyl and -amino.

Abstract: The present invention relates to methods of inducing differentiation of stem cells into a specific cell lineage, preferably lung cells. In particular, the invention relates to in vitro methods of inducing differentiation of stem cells into a specific cell lineage. The invention also relates to methods of producing and recovering differentiated stem cells of a specific cell lineage. The invention also includes differentiated stem cells and cell lineages produced by the methods of the present invention. In one aspect of the present invention there is provided a method of inducing differentiation of a stem cell into a specific cell lineage, preferably lung cells, the method including: culturing a stem cell in vitro in the presence of a tissue sample and/or extracellular medium of a tissue sample, under conditions that induce differentiation of the stem cell into a specific cell lineage, wherein the differentiated stem cell is the same cell type as the tissue sample.

Abstract: A method for diagnosing early stage renal disease and/or renal complications of a disease in which intact modified albumin is an indicator of the renal disease and/or complications.

Abstract: This invention relates to compounds to formula (1) wherein B is optionally substituted aryl; R1 and R2 are the same or different and are independently selected from hydrogen or C1-3 alkyl; n is 1 or 2, preferably n is 1; m is 0 or 1; R3 is hydrogen or acyl, R4 and R5 are the same or different and are independently selected from amino, alkylamino, dialkylamino, arylamino and C2-C4 cycloalkylamino; X and Y are independently selected from C, H or N provided at least one of X and Y is N; and salts thereof, solvates thereof, pharmaceutically acceptable derivatives thereof, prodrugs thereof, tautomers thereof and/or isomers thereof, and processes for their reparation and methods of treatment, pharmaceutical formulations and uses involving them.